Motion Sickness Drugs Market, Availability of over-the-counter (OTC) drugs to boost


NEW YORK, Sept. 30, 2022 /PRNewswire/ — Technavio’s latest offering, the Motion Sickness Drugs Market report provides a detailed analysis of the competitive scenario and the market growth across various regions. The motion sickness drugs market value is anticipated to grow by USD 119.64 million, at a CAGR of 4.15% during the forecast period.

Technavio has announced its latest market research report titled Global Motion Sickness Drugs Market 2022-2026

Technavio has announced its latest market research report titled Global Motion Sickness Drugs Market 2022-2026

Market Driver

One of the reasons influencing the growth of the market for motion sickness medications is the accessibility of over-the-counter (OTC) medications. The first-line treatment for repressing and preventing motion sickness symptoms has been anticholinergics and antihistamines. Numerous antihistamines are sold over-the-counter (OTC) and are suitable for usage by young patients. Furthermore, rather than being used to treat motion sickness, these medications are primarily utilized to avoid its effects.

OTC drugs are described as pharmaceuticals that are distributed directly to patients or consumers without a doctor’s prescription. The potential for patients to self-medicate for the treatment of minor sickness symptoms is made possible by the OTC availability of these medications, which also increases their accessibility and affordability. Request Free Sample Report.

Company Profiles

The motion sickness drugs market report includes information on the product launches, sustainability, and prospects of leading vendors including Aurobindo Pharma Ltd, Baxter International Inc., Caleb Pharmaceuticals Inc, Cipla Ltd., CVS Health Corp., DM Pharma, Dr Reddys Laboratories Ltd, GlaxoSmithKline Plc, Hylands, Johnson and Johnson, Lupin Ltd, Merck KGaA, Myungmoon Pharm Co. Ltd., Perrigo Co. Plc, Pfizer Inc., Prestige Consumer Healthcare Inc., Reliefband Technologies LLC, Viatris Inc., WellSpring Pharmaceutical Corp., and Zenomed Healthcare Pvt. Ltd. Buy Sample Report.

Competitive Analysis

The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Market Segmentation

To know additional highlights and key points on various market segments and their impact in coming years, Download Free Sample Report.

Related Reports

Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography – Forecast and Analysis 2022-2026

Lennox-Gastaut Syndrome Treatment Market by Type and Geography – Forecast and Analysis 2022-2026

Motion Sickness Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 4.15%

Market growth 2022-2026

$119.64 million

Market structure

Fragmented

YoY growth (%)

3.67

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key consumer countries

US, Canada, UK, Germany, and China

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Aurobindo Pharma Ltd, Baxter International Inc., Caleb Pharmaceuticals Inc, Cipla Ltd., CVS Health Corp., DM Pharma, Dr Reddys Laboratories Ltd, GlaxoSmithKline Plc, Hylands, Johnson and Johnson, Lupin Ltd, Merck KGaA, Myungmoon Pharm Co. Ltd., Perrigo Co. Plc, Pfizer Inc., Prestige Consumer Healthcare Inc., Reliefband Technologies LLC, Viatris Inc., WellSpring Pharmaceutical Corp., and Zenomed Healthcare Pvt. Ltd

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Product

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

(PRNewsfoto/Infiniti Research, Inc.)

(PRNewsfoto/Infiniti Research, Inc.)

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/motion-sickness-drugs-market-availability-of-over-the-counter-otc-drugs-to-boost-market-growth—technavio-301636549.html

SOURCE Technavio



Read More: Motion Sickness Drugs Market, Availability of over-the-counter (OTC) drugs to boost

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments